Breaking News, Collaborations & Alliances

Pfizer, YaoPharma Enter Exclusive Alliance for GLP-1 Candidate

Aim to further develop, manufacture and commercialize YP05002 for weight management worldwide.

Author Image

By: Charlie Sternberg

Associate Editor

Pfizer Inc. has entered into an exclusive global collaboration and license agreement with YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Limited, a global healthcare company, for the development, manufacturing and commercialization of YP05002, a small molecule glucagon-like peptide 1 (GLP-1) receptor agonist currently in Phase 1 development for chronic weight management. “We look forward to contributing our expertise and resources to continue the development of this inv...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters